Changes in Beneficial Ownership · 4
Evommune, Inc.
EVMNNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
primarydocument.xml
Filing details
- Report period
- 2026-09-30
- Issuer
- Evommune, Inc.
- Issuer CIK
- 0002044725
- Trading symbol
- EVMN
Reporting owner 1
- Name
- Pena Luis C.
- Reporting owner CIK
- 0001620548
- Relationship
- Director · Officer
- Officer title
- President & CEO
- Address
- C/O EVOMMUNE, INC., 1891 PAGE MILL ROAD, PALO ALTO, CA, 94304
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-30 | A · Form 4 | 1,115.00[F1] | A | 7.02[F2] | 631,573.00 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
Remarks
This transaction is being reported late due to an administrative oversight.
Signature 1
- Signed
- /s/ Gregory S. Moss, Attorney-in-Fact
- Date
- 2026-10-15
Company context
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.